Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
07:30am, Thursday, 01'st Jul 2021
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S
CRISPR: 4 Emerging Players
09:06am, Wednesday, 30'th Jun 2021
CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agr
Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside
01:00pm, Tuesday, 22'nd Jun 2021
Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer. Cellectis offers a spec
• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidat
Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021
02:30am, Wednesday, 02'nd Jun 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
04:30pm, Tuesday, 11'th May 2021
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
04:30pm, Thursday, 06'th May 2021
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary techno
Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021
04:39pm, Monday, 26'th Apr 2021
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).
Monthly information on share capital and company voting rights
04:30pm, Monday, 12'th Apr 2021
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis Completes Sale of $47 million through its ATM program
02:30am, Friday, 09'th Apr 2021
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary tech
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
04:50pm, Monday, 29'th Mar 2021
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary tech
Monthly information on share capital and company voting rights
04:30pm, Friday, 12'th Mar 2021
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis S.A. (CLLS) CEO André Choulika on Q4 2020 Results - Earnings Call Transcript
03:15pm, Friday, 05'th Mar 2021
Cellectis S.A. (CLLS) CEO André Choulika on Q4 2020 Results - Earnings Call Transcript
Cellectis: Q4 Earnings Insights
05:22pm, Thursday, 04'th Mar 2021
Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 20.55% year over year to ($0.88), which missed the e
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
04:42pm, Thursday, 04'th Mar 2021
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene
